-transparent.png){kind=logo}
The pharmacokinetics of a single dose of ranitidine 50 mg iv were determined in ten normal-weight and ten morbidly obese (greater than 90 percent ideal body weight) age-matched female subjects. No significant difference between normal and obese subjects was found in ranitidine peak serum concentration, volume of distribution, clearance, and elimination rate constant. Ranitidine volume of distribution and clearance were significantly smaller in the obese subjects per kilogram of total body weight (1.45 vs. 0.80 L/kg and 0.59 vs. 0.33 L/h/kg, respectively; p less than 0.001) but not when normalized to ideal body weight (1.65 vs. 1.45 L/kg and 0.68 vs. 0.59 L/h/kg). We conclude that obese patients receiving ranitidine therapy should be treated with standard dosages or dosages based on ideal body weight.
R L Davis, and
R W Quenzer, and
H P Bozigian, and
C W Warner
April 1980,
American journal of hospital pharmacy,
R L Davis, and
R W Quenzer, and
H P Bozigian, and
C W Warner
October 1979,
Clinical pharmacology and therapeutics,
R L Davis, and
R W Quenzer, and
H P Bozigian, and
C W Warner
November 1991,
Anaesthesia,
R L Davis, and
R W Quenzer, and
H P Bozigian, and
C W Warner
August 1991,
Surgery, gynecology & obstetrics,
R L Davis, and
R W Quenzer, and
H P Bozigian, and
C W Warner
April 1982,
Antimicrobial agents and chemotherapy,
R L Davis, and
R W Quenzer, and
H P Bozigian, and
C W Warner
January 1981,
Biopharmaceutics & drug disposition,
R L Davis, and
R W Quenzer, and
H P Bozigian, and
C W Warner
January 2015,
Gynecologic and obstetric investigation,
R L Davis, and
R W Quenzer, and
H P Bozigian, and
C W Warner
February 1986,
Anesthesia and analgesia,
R L Davis, and
R W Quenzer, and
H P Bozigian, and
C W Warner
October 2007,
The Annals of pharmacotherapy,
R L Davis, and
R W Quenzer, and
H P Bozigian, and
C W Warner
January 2020,
Obstetrics and gynecology,
